Treatment of advanced or recurrent cervical cancer

doi:10.3760/cma.j.issn.1673-422X.2018.01.010

Abstract

Abstract: The treatment of advanced or recurrent cervical cancer is difficult in clinic. Most of the patients have lost the opportunities for surgery or radiotherapy. Palliative treatment with chemotherapy is the main treatment. In recent years, the intensive studies on molecular targeted therapy and immunotherapy have provided a new treatment strategy for patients with advanced or recurrent cervical cancer, improving the efficacy and quality of life of patients.

Key words: Uterine cervical neoplasms, Drug therapy, Immunotherapy, Molecular targeted therapy

Li Dan*, Lou Hanmei. Treatment of advanced or recurrent cervical cancer[J]. Journal of International Oncology, 2018, 45(1): 44-.

References

［1］ Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer［J］. Am J Obstet Gynecol, 2016, 214(1): 2230. DOI: 10.1016/j.ajog.2015.07.022. ［2］ Thigpen T. The role of chemotherapy in the management of carcinoma of the cervix［J］. Cancer J, 2003, 9(5): 425432. ［3］ Moore DH, Blessing JA, McQuellon RP, et al. Phase Ⅲ study of cisplatin with or without paclitaxel in stage ⅣB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study［J］. J Clin Oncol, 2004, 22(15): 31133119. DOI: 10.1200/JCO.2004.04.170. ［4］ Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase Ⅲ trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oneology Group Study［J］. J Clin Oncol, 2005, 23(21): 46264633. DOI: 10.1200/JCO.2005.10.021. ［5］ Monk BJ, Sill MW, McMeekin DS, et al. Phase Ⅲ trial of four cisplatincontaining doublet combinations in stage ⅣB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group study［J］. J Clin Oncol, 2009, 27(28): 46494655. DOI: 10.1200/JCO.2009.21.8909. ［6］ Matoda M, Tanigawa T, Omatsu K, et al. Platinumfree interval in secondline chemotherapy for recurrent cervical cancer［J］. Int J Gynecol Cancer, 2013(23): 16701674. DOI: 10.1097/IGC.0b013e3182a80a07. ［7］ Nishio S, Kitagawa R, Shibata T, et al. Prognostic factors from a randomized phase Ⅲ trial of Paclitaxel and carboplatin versus paclitaxel and cisplatin in metastaticor recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505S1［J］. Cancer Chemother Pharmacol, 2016, 78(4): 785790. DOI: 10.1007/s0028001631334. ［8］ Tanioka M, Katsumata N, Yonemori K, et al. Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy［J］. Cancer Chemother Pharmacol, 2011, 68(2): 337342. DOI: 10.1007/s0028001014947. ［9］ Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the openlabel randomized phase Ⅲ trial (JCOG0505)［J］. J Clin Oncol, 2015, 33(19): 21292135. DOI: 10.1200/JCO.2014.58.4391. ［10］ Lorusso D, Ferrandin G, Pignata S, et al. Evaluation of pemetrexed (Alimta, LY231514) as secondline chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group［J］. Ann Oncol, 2010, 21(1): 6166. DOI: 10.1093/annonc/mdp266. ［11］ Miller DS, Blessing JA, Ramondetta LM, et al. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase Ⅱ trial of the gynecologic oncology group［J］. J Clin Oncol, 2014, 32(25): 27442749. DOI: 10.1200/JCO.2013.54.7448. ［12］ Alberts DS, Blessing JA, Landrum LM, et al. Phase Ⅱ trial of nabpaclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study［J］. Gynecol Oncol, 2012, 127(3): 451455. DOI: 10.1016/j.ygyno.2012.09.008. ［13］ Yamamoto K, Izumi R, Hasegawa K, et al. Adjuvant oral 5fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report［J］. Int J Oncol, 2004, 24(5): 11751179. DOI: 10.3892/ ijo.24.5.1175. ［14］ Katsumata N, Hirai Y, Kamiura S, et al. Phase Ⅱ study of S1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer［J］. Ann Oncol, 2011, 22(6): 13531357. DOI: 10.1093/annonc/mdq602. ［15］ Phase Ⅲ study of S1 + cisplatin vs cisplatin in cervical cancer. 2016.NCT00770874［DB/OL］ . https://clinicaltrials.gov. ［16］ Mitsuhashi A, Suzuka K, Yamazawa K, et al. Serum vascular endothelial growth factor (VEGF) and VEGFC levels as tumor markers in patients with cervical carcinoma［J］. Cancer, 2005, 103(4): 724730. DOI: 10.1002/cncr.20819. ［17］ Tewari KS, Sill MW, Long IH, et al. Improved survival with bevacizumab in advanced cervical cancer［J］. N Engl J Med, 2014, 370(8): 734743. DOI: 10.1056/NEJMoa1309748. ［18］ Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, openlabel, phase 3 trial (Gynecologic Oncology Group 240)［J］. Lancet, 2017, 390(10103): 16541663. DOI: 10.1016/S01406736(17)316070. ［19］ Penson RT, Huang HQ, Wenzel LB, et al. Bevacizumab for advanced cervical cancer: patientreported outcomes of a randomised, phase 3 trial (NRG OncologyGynecologic Oncology Group protocol 240)［J］. Lancet Oncol, 2015, 16(3): 301311. DOI: 10.1016/S14702045(15)700045. ［20］ Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase Ⅲ trial［J］. J Clin Oncol, 2010, 28(6): 10611068. DOI: 10.1200/JCO.2009.23.9764. ［21］ Monk BJ, Pandite LN. Survival data from a phase Ⅱ, openlabel study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer［J］. J Clin Oncol, 2011, 29(36): 4845. DOI: 10.1200/JCO.2011.38.8777. ［22］ ConesaZamora P, TorresMoreno D, Isaac MA, et al. Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cellcycle markers and HPV presence［J］. Exp Mol Pathol, 2013, 95(2): 151155. DOI: 10.1016/j.yexmp.2013.06.011. ［23］ Goncalves A, Fabbro M, Lhommé C, et al. A phase Ⅱ trial to evaluate gefitinib as second or thirdline treatment in patients with recurring locoregionally advanced or metastatic cervical cancer［J］. Gynecol Oncol, 2008, 108(1): 4246. DOI: 10.1016/j.ygyno.2007.07.057. ［24］ Woodworth CD, Diefendorf LP, Jette DF, et al. Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by human papillom avirus type 16［J］. Virology, 2011, 421(1): 1927. DOI: 10.1016/j.virol.2011.09.014. ［25］ Schilder RJ, Sill MW, Lee YC, et al. A phase Ⅱ trial of erlotinib in recurrent squamous cell carcinom a of the cervix: a Gynecologic Oneology Group Study［J］. Gynecol Cancer, 2009, 19(5): 929933. DOI: 10.1111/IGC.0b013e3181a83467. ［26］ NogueiraRodrigues A, Moralez G, Grazziotin R, et al. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer［J］. Cancer, 2014, 120(8): 11871193. DOI: 10.1002/cncr.28471. ［27］ Kurtz JE, HardyBessard AC, Deslandres M, et al. Cetuximab, topoteean and cisplatin for the treatment of advanced cervical cancer: a phase Ⅱ GINECO trial［J］. Gynecol Oncol, 2009, 113(1): 1620. DOI: 10.1016/j.ygyno.2008.12.040. ［28］ Hertlein L, Lenhard M, Kirschenhofer AA, et al. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients［J］. Arch Gynecol Obstet, 2011, 283(1): 109113. DOI: 10.1007/s0040401013891. ［29］ Farley J, Sill MW, Birrer M, et al. Phase Ⅱ study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study［J］. Gynecol Oncol, 2011, 121(2): 303308. DOI: 10.1016/j.ygyno.2011.01.030. ［30］ Cetina L, Crombet T, JiménezLima R, et al. A pilot study of nimotuzumab plus single agent chemotherapy as second or thirdline treatment or more in patients with recurrent, persistent or metastatic cervical cancer［J］. Cancer Biol Ther, 2015, 16(5): 684689. DOI: 10.1080/15384047.2015.1026483. ［31］ Molinolo AA, Marsh C, El Dinali M, et al. mTOR as a molecular target in HPVassociated oral and cervical squamous carcinomas［J］. Clin Cancer Res, 2012, 18(9): 25582568. DOI: 10.1158/10780432.CCR112824. ［32］ Tinker A, Mackay H, Ellard S, et al. Preliminary activity of temsirolimus, an mTOR inhibitor, in patients with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix: a NCICCTG Phase Ⅱ Clinical Trial［J］. Mol Cancer Ther, 2011, 10 Suppl 1: C69. DOI: 10.1158/15357163.TARG11C69. ［33］ Tinker AV, Ellard S, Welch S, et al. Phase Ⅱ study of ternsirolimus (CCI779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical trials Group (NCIC CTG IND 199)［J］. Gynecol Oncol, 2013, 130(2): 269274. DOI: 10.1016/j.ygyno.2013.05.008. ［34］ Thaker PH, Salani R, Brady WE, et al. A phase Ⅰ trial of paclitaxel cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT01281852)［J］. Ann Oncol, 2017, 28(3): 505511. DOI: 10.1093/annonc/mdw635. ［35］ Kunos C, Deng W, Dawson D, et al. A phase ⅠⅡ evaluation of veliparib (NSC737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study［J］. Int J Gynecol Cancer, 2015, 25(3): 484492. DOI: 10.1097/IGC0000000000000380. ［36］ CouzinFrankel J. Breakthrough of the year 2013. Cancer immunotherapy［J］. Science, 2013, 342(6165): 14321433. DOI: 10.1126/science.342.6165.1432. ［37］ Yang W, Lu YP, Yang YZ, et al. Expressions of programmed death (PD)1 and PD1 ligand (PDL1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status［J］. J Obstet Gynaecol Res, 2017, 43(10): 16021612. DOI: 10.1111/jog.13411. ［38］ An investigational immunotherapy study to investigate the safety and effectiveness of nivolumab, and nivolumab combination therapy in virusassociated tumors (CheckMate358). 2015.NCT02488759［DB/OL］ . https://clinicaltrials.gov.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[3]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[6]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[7]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[8]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[9]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[10]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[11]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[12]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[13]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[14]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[15]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.